In April 2016, we opened the doors of a scientific laboratory that now operates 24 hours a day, 7 days a week. We conduct research into methods of cancer immunotherapy using cell-derived products in collaboration with our partners from Lithuania, Austria, Estonia and the Czech Republic

 

   We are currently conducting scientific researches with partners such as the National Cancer Institute, the Joint Center for Life Sciences and the Center for Innovative Medicine.

​

Currently ongoing scientific research:

1.MITA project “In vitro study of anticancer properties of recombinant protein”

 

The recombinant Gc protein analogue developed in the company can be used in cancer patients as a potent activator of the immune system, i.e. drug for additional immunostimulation. According to the original hypotheses, the recombinant protein produced in-house can efficiently activate macrophages and thus promote anti-cancer immune responses.

 

Our partner in this project – National Cancer Institute.

​

Completed scientific researches:

2.Medicinal products for modulating the immune system in the field of advanced therapies for cancer treatment

​

During this project, it was planned to develop a new products: anti-cancer therapeutic autologous dendritic cell vaccines in which the immune response would be modulated using autologous or allogeneic exosomes. They could be used to treat three different cancer locations: glioblastoma, melanoma, and lung cancer.

​

We ran the project together with the National Cancer Institute. The project started in 2017. March 1st, 2017 and completed in early 2019.

​

3.Effectiveness of therapeutic anticancer vaccines in experimental models using mice

​

The purpose of this experimental research was to evaluate and compare the effectiveness of anticancer, autologous and xenogeneic vaccines using in vivo models of melanoma and lung carcinoma in mice.

​

The research was carried out with our partners from the National Cancer Institute, Innovita Research, JSC and the R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology in Ukraine. The project started in September 2015 and completed in 2017 autumn.